355 related articles for article (PubMed ID: 31704290)
1. Tanshinone IIA ameliorates the bleomycin-induced endothelial-to-mesenchymal transition via the Akt/mTOR/p70S6K pathway in a murine model of systemic sclerosis.
Jiang Y; Hu F; Li Q; Shen C; Yang J; Li M
Int Immunopharmacol; 2019 Dec; 77():105968. PubMed ID: 31704290
[TBL] [Abstract][Full Text] [Related]
2. Bone morphogenetic protein-7 inhibits endothelial-to-mesenchymal transition in primary human umbilical vein endothelial cells and mouse model of systemic sclerosis via Akt/mTOR/p70S6K pathway.
Shen C; Jiang Y; Li Q; Liu C; Hu F; Li M
J Dermatol Sci; 2021 Aug; 103(2):82-92. PubMed ID: 34266726
[TBL] [Abstract][Full Text] [Related]
3. Tanshinone IIA ameliorates the development of dermal fibrosis in systemic sclerosis.
Jiang Y; Hu F; Li M; Li Q
Clin Exp Pharmacol Physiol; 2024 Feb; 51(2):e13834. PubMed ID: 38037494
[TBL] [Abstract][Full Text] [Related]
4. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.
Manetti M; Romano E; Rosa I; Guiducci S; Bellando-Randone S; De Paulis A; Ibba-Manneschi L; Matucci-Cerinic M
Ann Rheum Dis; 2017 May; 76(5):924-934. PubMed ID: 28062404
[TBL] [Abstract][Full Text] [Related]
5. Tanshinone IIA ameliorates bleomycin-induced pulmonary fibrosis and inhibits transforming growth factor-beta-β-dependent epithelial to mesenchymal transition.
Tang H; He H; Ji H; Gao L; Mao J; Liu J; Lin H; Wu T
J Surg Res; 2015 Jul; 197(1):167-75. PubMed ID: 25911951
[TBL] [Abstract][Full Text] [Related]
6. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway.
Zhou J; Jiang YY; Chen H; Wu YC; Zhang L
Cell Prolif; 2020 Feb; 53(2):e12739. PubMed ID: 31820522
[TBL] [Abstract][Full Text] [Related]
7. Tanshinone IIA attenuates silica-induced pulmonary fibrosis via Nrf2-mediated inhibition of EMT and TGF-β1/Smad signaling.
Feng F; Cheng P; Xu S; Li N; Wang H; Zhang Y; Wang W
Chem Biol Interact; 2020 Mar; 319():109024. PubMed ID: 32097614
[TBL] [Abstract][Full Text] [Related]
8. Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB‑152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway.
Teng Z; Xu S; Lei Q
Oncol Rep; 2020 Feb; 43(2):503-515. PubMed ID: 31894340
[TBL] [Abstract][Full Text] [Related]
9. Tanshinone IIA alleviates acute ethanol-induced myocardial apoptosis mainly through inhibiting the expression of PDCD4 and activating the PI3K/Akt pathway.
Deng H; Yu B; Li Y
Phytother Res; 2021 Aug; 35(8):4309-4323. PubMed ID: 34169595
[TBL] [Abstract][Full Text] [Related]
10. Tanshinone IIA regulates glycogen synthase kinase-3β-related signaling pathway and ameliorates memory impairment in APP/PS1 transgenic mice.
Peng X; Chen L; Wang Z; He Y; Ruganzu JB; Guo H; Zhang X; Ji S; Zheng L; Yang W
Eur J Pharmacol; 2022 Mar; 918():174772. PubMed ID: 35090935
[TBL] [Abstract][Full Text] [Related]
11. Dihydroartemisinin alleviates skin fibrosis and endothelial dysfunction in bleomycin-induced skin fibrosis models.
Li R; Yin H; Wang J; He D; Yan Q; Lu L
Clin Rheumatol; 2021 Oct; 40(10):4269-4277. PubMed ID: 34013490
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib attenuates renal interstitial fibrosis in kidney transplantation via regulating the EMT induced by TNF-α-Smurf1-Akt-mTOR-P70S6K pathway.
Zhou J; Cheng H; Wang Z; Chen H; Suo C; Zhang H; Zhang J; Yang Y; Geng L; Gu M; Tan R
J Cell Mol Med; 2019 Aug; 23(8):5390-5402. PubMed ID: 31140729
[TBL] [Abstract][Full Text] [Related]
13. Tanshinone IIA attenuates interleukin-17A-induced systemic sclerosis patient-derived dermal vascular smooth muscle cell activation via inhibition of the extracellular signal-regulated kinase signaling pathway.
Liu M; Yang J; Li M
Clinics (Sao Paulo); 2015 Apr; 70(4):250-6. PubMed ID: 26017791
[TBL] [Abstract][Full Text] [Related]
14. Tanshinone IIA affects the malignant growth of Cholangiocarcinoma cells by inhibiting the PI3K-Akt-mTOR pathway.
Liu H; Liu C; Wang M; Sun D; Zhu P; Zhang P; Tan X; Shi G
Sci Rep; 2021 Sep; 11(1):19268. PubMed ID: 34588580
[TBL] [Abstract][Full Text] [Related]
15. Salvianolic acid B and tanshinone IIA attenuate myocardial ischemia injury in mice by NO production through multiple pathways.
Pan C; Lou L; Huo Y; Singh G; Chen M; Zhang D; Wu A; Zhao M; Wang S; Li J
Ther Adv Cardiovasc Dis; 2011 Apr; 5(2):99-111. PubMed ID: 21282198
[TBL] [Abstract][Full Text] [Related]
16. Vertical inhibition of PI3K/Akt/mTOR signaling demonstrates in vitro and in vivo anti-fibrotic activity.
Liang M; Lv J; Chu H; Wang J; Chen X; Zhu X; Xue Y; Guan M; Zou H
J Dermatol Sci; 2014 Nov; 76(2):104-11. PubMed ID: 25258031
[TBL] [Abstract][Full Text] [Related]
17. Tanshinone IIA induces mitochondria dependent apoptosis in prostate cancer cells in association with an inhibition of phosphoinositide 3-kinase/AKT pathway.
Won SH; Lee HJ; Jeong SJ; Lee HJ; Lee EO; Jung DB; Shin JM; Kwon TR; Yun SM; Lee MH; Choi SH; Lü J; Kim SH
Biol Pharm Bull; 2010; 33(11):1828-34. PubMed ID: 21048307
[TBL] [Abstract][Full Text] [Related]
18. Tanshinone IIA protects against myocardial ischemia reperfusion injury by activating the PI3K/Akt/mTOR signaling pathway.
Li Q; Shen L; Wang Z; Jiang HP; Liu LX
Biomed Pharmacother; 2016 Dec; 84():106-114. PubMed ID: 27643552
[TBL] [Abstract][Full Text] [Related]
19. Tanshinone IIA regulates CCl
Li Q; Huang D; Liao W; Su X; Li J; Zhang J; Fang M; Liu Y
J Biochem Mol Toxicol; 2024 Feb; 38(2):e23648. PubMed ID: 38348705
[TBL] [Abstract][Full Text] [Related]
20. Tanshinone IIA Ameliorates Streptozotocin-Induced Diabetic Nephropathy, Partly by Attenuating PERK Pathway-Induced Fibrosis.
Xu S; He L; Ding K; Zhang L; Xu X; Wang S; Qian X
Drug Des Devel Ther; 2020; 14():5773-5782. PubMed ID: 33408464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
